摘要
近年来,肿瘤免疫疗法席卷全球,相关研究及应用领域激增。程序性死亡受体-1(PD-1)/程序性死亡配体-1(PD-L1)抑制剂在肺癌、黑色素瘤、乳腺癌和淋巴瘤等适应证上的广泛使用,掀起了免疫抑制剂相关领域的研究热点。PD-1/PD-L1抑制剂通过增强自身免疫系统的活性而引起免疫系统相关的副作用,包括引起相关心脏毒性,通常表现为心肌炎、心包疾病、心律失常、心源性休克或猝死等,因其表现多样、致死率高,所以引起学者的关注。本文就PD-1/PD-L1抑制剂相关心脏毒性的机制、流行病学、作用特点、监测及管理进行综述。
Recently,tumor immunotherapy has swept the world and the related research and application fields have surged.The widespread use of programmed death-1(PD-1)/programmed death ligand-1(PD-L1)inhibitors in the indications such as lung cancer,melanoma,breast cancer and lymphoma has raised much research hotspots.PD-1/PD-L1 blockers cause immune system related side effects(including related cardiotoxicity)by boosting the activity of your own immune system,usually manifested as myocarditis,pericardial disease,arrhythmia,cardiogenic shock or sudden death.Because of its diverse manifestations and high mortality,many scholars have payed attention to this problem.This paper reviews the mechanism,epidemiology,clinical feature,monitoring and management of PD-1/PDL1 inhibitor related cardiotoxicity.
作者
沈珈谊
吕玲春
韦铁民
Shen Jiayi;Lv Lingchun;Wei Tiemin(Department of Cardiology,Lishui Hospital,Zhejiang University School of Medicine,Lishui 323000,China)
出处
《心脑血管病防治》
2023年第1期49-51,共3页
CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT
基金
浙江省基础公益研究计划(LGF19H020008)
丽水市公益技术应用研究(2019GYX28)
作者简介
通信作者:韦铁民,Email:lswtm@sina.com
